“Our chemotherapy and radiation therapy volumes have been very robust. Probably because of the NCI designation, we are seeing significantly more patients than last year,” Stephen D. Nimer, director of Sylvester Comprehensive Cancer Center, said to The Cancer Letter. “Compared to last year, we seem to be up about 15%. We’ve been growing by about 8% to 9% for quite some years. This year is even more.”
The past two decades have brought hope to myeloma patients, as the majority benefit from the significant advances in chemotherapy.
It is obvious to virtually everyone in the United States that the numbers of patients affected with COVID-19 are continuing to escalate. The impact of this is obvious, with many patients dying or permanently damaged from this dangerous virus.
In early March, when Giuseppe Curigliano, an oncologist in Milan, first spoke with The Cancer Letter about COVID-19, the situation in Italy was “like being in a war zone.”
As cases of COVID-19 surge in Florida, Lucio Gordan, managing physician and president of Florida Cancer Specialists and Research Institute, is working to increase the role of telehealth.
A conference organized by the American Association for Cancer Research July 20-22 will bring together oncologists from academia, industry and government to identify ways for cancer researchers to inform studies of COVID-19.
Yale Cancer Center researchers identified a leading mechanism behind the pathophysiology of COVID-19, and pinpointed a biological marker for the mechanism that may help with treatment.
Last time Ruben Mesa spoke with The Cancer Letter, COVID-19 was under control in San Antonio and the environs—or so it seemed.
The National Comprehensive Cancer Network published NCCN Guidelines for Patients: Immunotherapy Side Effects—Immune Checkpoint Inhibitors.
Approximately two-thirds of the NCI Community Oncology Research Programs, serve states in which the rural population exceeds 30%.
